PMID- 34550777
OWN - NLM
STAT- MEDLINE
DCOM- 20220207
LR  - 20220207
IS  - 1945-0257 (Electronic)
IS  - 1945-0257 (Linking)
VI  - 25
IP  - 9
DP  - 2021 Sep
TI  - PCSK9 E670G (rs505151) Variant and Coronary Artery Disease Risk Among Diabetics.
PG  - 615-623
LID - 10.1089/gtmb.2021.0010 [doi]
AB  - Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme in 
      the family of proprotein convertases implicated in lipid metabolism and is a 
      significant genetic risk factor in cardiovascular diseases among various 
      populations. Aim of the Study: This study explored the correlation between the 
      alleles of the rs505151 (E670G) locus of the PCSK9 gene and its expression levels 
      with coronary artery disease (CAD) risk in Egyptian patients with type 2 diabetes 
      mellitus (T2DM). Subjects and Methods: A case-control study was performed on 112 
      lean subjects compared to 100 T2DM patients without CAD and 84 T2DM patients with 
      CAD to investigate the relationships among PCSK9 expression levels, the E670G 
      (rs505151) gene variant, lipid concentrations, and CAD risk in an Egyptian 
      diabetic population. A restriction fragment length polymorphism-polymerase chain 
      reaction (PCR) assay was used to assess the gene polymorphism, and PCSK9 mRNA 
      expression was determined by quantitative real-time PCR. Results: The prevalence 
      of the E670G (rs505151) AG genotype in diabetics with CAD was significantly 
      greater than the other two groups. The PCSK9 gene expression levels in diabetics 
      with CAD were significantly greater than the other two groups. G allele carriers 
      (AG+GG) had a higher relative PCSK9 expression than A allele carriers. 
      Conclusion: PCSK9 relative expression levels and the E670G (rs505151) AG genotype 
      are CAD risk factors among Egyptian diabetics and are linked positively to the 
      atherogenic index of plasma.
FAU - Mohamed, Samy H
AU  - Mohamed SH
AD  - Medical Biochemistry Department, and Faculty of Medicine, University of Zagazig, 
      Zagazig, Egypt.
FAU - Hassaan, Mohamed M M
AU  - Hassaan MMM
AD  - Internal Medicine Department, Faculty of Medicine, University of Zagazig, 
      Zagazig, Egypt.
FAU - Ibrahim, Basma A
AU  - Ibrahim BA
AD  - Medical Biochemistry Department, and Faculty of Medicine, University of Zagazig, 
      Zagazig, Egypt.
FAU - Sabbah, Norhan A
AU  - Sabbah NA
AUID- ORCID: 0000-0003-2281-0621
AD  - Medical Biochemistry Department, and Faculty of Medicine, University of Zagazig, 
      Zagazig, Egypt.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PL  - United States
TA  - Genet Test Mol Biomarkers
JT  - Genetic testing and molecular biomarkers
JID - 101494210
RN  - EC 3.4.21.- (PCSK9 protein, human)
RN  - EC 3.4.21.- (Proprotein Convertase 9)
SB  - IM
MH  - Case-Control Studies
MH  - Coronary Artery Disease/epidemiology/*genetics
MH  - Diabetes Mellitus, Type 2/*complications/genetics
MH  - Egypt/epidemiology
MH  - Female
MH  - *Genetic Predisposition to Disease
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Polymorphism, Restriction Fragment Length
MH  - Polymorphism, Single Nucleotide
MH  - Proprotein Convertase 9/*genetics
MH  - Risk Factors
OTO - NOTNLM
OT  - AIP
OT  - CAD
OT  - E670G (rs505151)
OT  - PCSK9 expression
OT  - T2DM
EDAT- 2021/09/23 06:00
MHDA- 2022/02/08 06:00
CRDT- 2021/09/22 17:16
PHST- 2021/09/22 17:16 [entrez]
PHST- 2021/09/23 06:00 [pubmed]
PHST- 2022/02/08 06:00 [medline]
AID - 10.1089/gtmb.2021.0010 [doi]
PST - ppublish
SO  - Genet Test Mol Biomarkers. 2021 Sep;25(9):615-623. doi: 10.1089/gtmb.2021.0010.